{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:37:10Z","timestamp":1792089430283,"version":"4.4.0"},"reference-count":7,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ymthe.2022.09.020","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T03:47:44Z","timestamp":1666151264000},"page":"3335-3336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["First conditional marketing authorization approval in the European Union for hemophilia \u201cA\u201d gene therapy"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-745X","authenticated-orcid":false,"given":"Thierry","family":"VandenDriessche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn F.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslaw","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.09.020_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/hae.13494","article-title":"Haemophilia gene therapy: from trailblazer to gamechanger. Haemophilia","volume":"24","author":"Evens","year":"2018","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2022.09.020_bib2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.09.020_bib3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2022.09.020_bib4","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.09.020_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2022.07.005","article-title":"IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice","author":"Butterfield","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.09.020_bib6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.09.020_bib7","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1016\/j.ymthe.2021.10.025","article-title":"Eliminating Panglossian thinking in development of AAV therapeutics","volume":"29","author":"Kaczmarek","year":"2021","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622006098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622006098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:04:36Z","timestamp":1761501876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622006098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":7,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1525001622006098"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.09.020","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First conditional marketing authorization approval in the European Union for hemophilia \u201cA\u201d gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}